BRIEF published on 08/31/2026 at 07:05, 25 days 20 hours ago Advicenne withdraws the application for registration of ADV7103 in the United States FDA Pharmaceutical Registration Advicenna Sibnayal
PRESS RELEASE published on 08/31/2026 at 07:00, 25 days 20 hours ago Inside Information / Other news releases Advicenne voluntarily withdraws NDA for ADV7103 in the USA due to CMC-related work issues. Company hosting French webinar for shareholders. ADV7103 approved in EU, UK, KSA, UAE Pharmaceutical Webinar Advicenne ADV7103 NDA Withdrawal
BRIEF published on 07/16/2026 at 18:40, 2 months 9 days ago Advicenne's Revenue Surge in First Half of 2026 Revenue Growth Advicenne Sibnayal® Likozam® Pharmaceutical Sales
PRESS RELEASE published on 07/16/2026 at 18:35, 2 months 9 days ago Inside Information / Other news releases Advicenne reports significant revenue growth in first half of 2026 driven by Sibnayal® and Likozam® reimbursement in France, ending negative impact of early access rebates. Sales of Sibnayal® and Likozam® increased in volume Revenue Growth France Advicenne Sibnayal® Likozam®
BRIEF published on 07/01/2026 at 17:50, 2 months 24 days ago Unlimited renewal of the marketing authorization for Sibnayal® by Advicenne in the United Kingdom United Kingdom Advicenna Sibnayal Rare Kidney Diseases Marketing Authorization Renewal
BRIEF published on 06/22/2026 at 19:12, 3 months 3 days ago Advicenne Secures Financing to Q2 2027 with New Bond Issue Strategic Development Bond Financing FDA Registration Advicenne Rare Kidney Diseases
PRESS RELEASE published on 06/22/2026 at 19:07, 3 months 3 days ago Inside Information / Other news releases Advicenne secures €3.8 million bond financing, extending cash runway to Q2 2027, for FDA registration of ADV7103 in the USA Bond Financing FDA Registration Advicenne Cash Runway ADV7103
BRIEF published on 06/01/2026 at 07:50, 3 months 24 days ago Advicenne receives reimbursement for Likozam® and reduces its debt Advicenna Refund Likozam Debt Reduced Discounts Early Access
BRIEF published on 05/21/2026 at 21:07, 4 months 4 days ago Advicenne: Evolution of governance and challenges ahead Governance Pharmaceutical Restructuring Advicenna Sibnayal®
BRIEF published on 05/21/2026 at 21:07, 4 months 4 days ago Advicenne Announces Governance Changes Post-AGM Annual General Meeting Financial Restructuring Board Appointments Governance Changes Advicenne
Published on 09/26/2026 at 01:00, 2 hours 54 minutes ago Guanajuato Silver Renews Base Shelf Prospectus
Published on 09/26/2026 at 01:00, 2 hours 54 minutes ago Findev Inc. Provides Update on Victoria Park Loan Exposure and Expected Accounting Impairment
Published on 09/25/2026 at 22:15, 5 hours 39 minutes ago Rocky Shore Gold Closes First Tranche of Non-Brokered Private Placement
Published on 09/25/2026 at 17:30, 10 hours 24 minutes ago Goldcliff Announces Unit and Flow Through "LIFE" Offerings
Published on 09/25/2026 at 15:00, 12 hours 54 minutes ago HM Exploration Provides Program Update for the Lewis Pilley's Project
Published on 09/26/2026 at 00:01, 3 hours 53 minutes ago Photon Energy N.V. Sells 7.6 MWp of PV Operational Assets in Slovakia
Published on 09/25/2026 at 18:30, 9 hours 24 minutes ago 029 Group SE: Publication of Half-Year Report 2026
Published on 09/25/2026 at 17:30, 10 hours 24 minutes ago GEVELOT S.A.: Weekly declaration of share buybacks – 09/25/2026 (French only)
Published on 09/25/2026 at 17:17, 10 hours 37 minutes ago Amendments to the Bond Terms and Conditions Have Been Implemented
Published on 09/25/2026 at 17:40, 10 hours 14 minutes ago Availability of the 2026 half-year financial report
Published on 09/24/2026 at 18:00, 1 day 9 hours ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2026
Published on 09/24/2026 at 18:00, 1 day 9 hours ago GUILLEMOT CORPORATION: 2026 CONSOLIDATED INTERIM RESULTS
Published on 09/24/2026 at 17:45, 1 day 10 hours ago Cegedim first-half 2026 results: profitability continues to improve
